Sanofi and CD&R Finalize Opella Share Purchase Agreement

Sanofi and Clayton, Dubilier & Rice (CD&R) have concluded a share purchase agreement concerning the sale of a 50% stake in Opella. This transaction will see Bpifrance joining as a minority shareholder with an approximate 2% share, while Sanofi retains a significant stake. The transaction terms remain unchanged from previous announcements, and the finalization is anticipated in Q2 2025.

The deal is still awaiting customary regulatory approvals from relevant authorities. The transaction underscores a strategic move for Sanofi, aligning with their broader objectives. Any realization of the transaction’s benefits will depend on meeting required conditions and obtaining necessary clearances.